In one of the largest regenerative medicine deals of 2026 to date, UCB has announced plans to acquire Neurona Therapeutics in a transaction valued at an astounding price tag: up to $1.15 billion. The deal includes $650 million upfront, with an additional $500 million tied to future milestones, underscoring the scale of UCB’s commitment to next-generation therapeutic modalities. [Read more…]
BREAKING: Gilead Sciences to Acquire Arcellx a Staggering $7.8 Billion CAR-T Cell Therapy Deal
Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
Charles River Laboratories Completes Acquisition of HemaCare for $380 Million Cash
Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share. [Read more…]
CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank
CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR). According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”
The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.
With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.
[Read more…]
Cell Care Australia Acquires Insception Lifebank in Canada
The largest cord blood bank in Australia, Cell Care, has announced that it is acquiring the largest cord blood bank in Canada, Insception Lifebank. This acquisition is part of a larger trend occurring within the cord blood banking industry, which is the trend of maturation and consolidation.
Over the past five years, the cord blood and tissue marketplace has undergone substantial consolidation. One major event was the acquisition of the United States’ largest cord blood, Cord Blood Registry (CBR), by AMAG Pharmaceuticals for $700M in March of 2015. Previously, ViaCord had been acquired by the multinational company PerkinElmer in October 2007 for $300M. [Read more…]